Replies to post #14418 on Todos Med Ltd (TOMDF)

[redspeed]

Here's 3 updates for you. I got tired of cutting and pasting so you can find the rest. Keep in mind Todos doesn't control the timing of the analysis and when the data is finalized.

Gerald Commissiong@G_Commish Aug 4
Replying to @QuartersFloor
Smart! Waiting for the final Part 2 LymPro Alzheimer’s test data. Connected with Dr. Arendt a couple of weeks ago and he was mid analysis. Very exciting - amyloid proving to be the tail wagging the dog. Cell cycle dysregulation is driving AD pathology

Smart! Waiting for the final Part 2 LymPro Alzheimer’s test data. Connected with Dr. Arendt a couple of weeks ago and he was mid analysis. Very exciting - amyloid proving to be the tail wagging the dog. Cell cycle dysregulation is driving AD pathology

— Gerald Commissiong (@G_Commish) August 4, 2022

Gerald Commissiong@G_Commish Aug 30
Replying to @gianlucac1 @ThManfredi and 4 others
Interesting... that's exactly what we find with LymPro in Alzheimer's disease patients vs. non-Alzheimer's dementia. I think I already know where this story is headed, and now LymPro likely just went way up in value and necessity $TOMDF

Interesting... that's exactly what we find with LymPro in Alzheimer's disease patients vs. non-Alzheimer's dementia. I think I already know where this story is headed, and now LymPro likely just went way up in value and necessity $TOMDFhttps://t.co/Svg5Ko2qCQ

— Gerald Commissiong (@G_Commish) August 30, 2022

Gerald Commissiong@G_Commish 6:42 AM · Sep 28, 2022
Part 2 data coming out Q4. Given #lecanemab likely on market 2023, early diagnosis now more important than ever.
investor.todosmedical.com
Todos Medical Announces Positive Alzheimer's Biomarker Clinical Data from LymPro vs. Amyloid PET...

$TOMDF Todos Medical Announces Positive #Alzheimers Biomarker Clinical Data from #LymPro vs. Amyloid PET Interim Analysis p=0.0000216 R =0.85

Part 2 data coming out Q4. Given #lecanemab likely on market 2023, early diagnosis now more important than ever.https://t.co/CrgGJKuEqt

— Gerald Commissiong (@G_Commish) September 28, 2022